$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
CDK4/6抑制剂瑞博西利给乳腺癌晚期带来了哪些好处?
2025-10-19 11:44:20
Check Details
瑞博西林是治疗HR+/HER2-绝经后晚期乳腺癌的口服抗癌靶向药
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利治疗乳腺癌晚期的效果显著
2025-10-19 11:44:20
Check Details
奥拉帕利治疗HER2阴性转移性乳腺癌的安全性和耐受性
2025-10-19 11:44:20
Check Details
瑞博西林可有效提高HR+/HER2-绝经前晚期乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
乳腺癌患者服用爱博新进行治疗能活多久?
2025-10-19 11:44:20
Check Details
奥拉帕利可以用于治疗三阴性乳腺癌患者吗?
2025-10-19 11:44:20
Check Details
瑞博西林的出现,使绝经前晚期乳腺癌患者获益
2025-10-19 11:44:20
Check Details
三阴性乳腺癌可以使用爱博新进行治疗吗?
2025-10-19 11:44:20
Check Details
瑞博西林对晚期乳腺癌有着不错的效果
2025-10-19 11:44:20
Check Details
奥拉帕利是乳腺癌的一线维持治疗用药吗?
2025-10-19 11:44:20
Check Details
乳腺癌治疗药物爱博新多少钱一瓶?去哪买的到?
2025-10-19 11:44:20
Check Details
1
2
...
2003
2004
2005
2006
2007
2008
2009
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
2
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
3
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
8
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
9
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
10
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
11
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
12
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity